Læknablaðið - 15.01.2012, Síða 30

RANNSÓKN
Heimildir
1. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B,
Vilacosta I, et al. Guidelines on the prevention, diagnosis,
and treatment of infective endocarditis (new version
2009): the Task Force on the Prevention, Diagnosis, and
Treatment of Infective Hndocarditis of the European
Society of Cardiology (ESC). Eur Heart J 2009; 30:2369-413.
2. Eiriksson H, Thorgeirsson G, Thorsteinsson SB.
Hjartaþelsbólga á íslandi 1976-1989. Læknablaðið 1989:75;
149-55.
3. Osler W. The Gulstonian Lectures, on Malignant
Endocarditis. Br Med J1885; 1:577-9.
4. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet
A, Briangon S, et al. Changing profile of infective
endocarditis: results of a 1-year survey in France. JAMA
2002; 288: 75-81.
5. Habib G, Thuny F, Avierinos JF. Prosthetic valve
endocarditis: current approach and therapeutic options.
Progr Cardiovasc Dis 2008; 50: 274-81.
6. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG
Jr, Bayer AS, et al. Clinical presentation, etiology, and
outcome of infective endocarditis in the 21st century: the
International Collaboration on Endocarditis-Prospective
Cohort Study. Arch Intem Med 2009; 169:463-73.
7. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T,
et al. Proposed modifications to the Duke criteria for the
diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:
633-8.
8. Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey
KR, Steckelberg JM, et al. A systematic review of
population-based studies of infective endocarditis. Chest
2007; 132:1025-35.
9. Bouza E, Menasalvas A, Munoz P, Vasallo FJ, del Mar
Moreno M, Garcia Femandez M A. Infective endocarditis--a
prospective study at the end of the twentieth century: new
predisposing conditions, new etiologic agents, and still a
high mortality. Medicine (Baltimore) 2001; 80:298-307.
10. Silverman ME, Upshaw CB Jr. Extracardiac manifestations
of infective endocarditis and their historical descriptions.
Am J Cardiol 2007; 100:1802-7.
11. Loupa C, Mavroidi N, Boutsikakis I, Paniara O, Deligarou
O, Manoli H, et al. Infective endocarditis in Greece: a
changing profile. Epidemiological, microbiological and
therapeutic data. Clin Microbiol Infect 2004; 10:556-61.
12. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L,
Paré Cet al. Contemporary clinical profile and outcome of
prosthetic valve endocarditis. JAMA 2007; 297:1354-61.
13. Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ,
Sexton DJ, et al. Changing patient characteristics and the
effect on mortality in endocarditis. Arch Int Med 2002; 162:
90-4.
14. Moreillon P, Que YA. Infective endocarditis. Lancet 2004;
363:139-49.
15. Prendergast BD, Tomos P. Surgery for infective
endocarditis: who and when? Circulation 2010; 121: 1141-
52.
ENGLISH SUMMARY
Endocarditis in lceland 2000-2009, a national survey incidence, microbiology and prognosis
Tryggvadottir EB', Agnarsson UT’ 2, Sverrisson JT3, Thorsteinsson SB2, Högnason JV2 Thorgeirsson G2
Introduction: The objective of this study was to analyze the incidence,
clinical features, microbiology and prognosis of patients with infective
endocarditis (IE) in lceland, and to compare the results with a previous
study made in lceland 1976-85.
Material and Methods: A retrospective study including all patients
diagnosed with IE in lceland 2000-2009. Information was obtained from
medical records.
Results: A total of 88 cases (71 % men, mean age 59 years) were diagno-
sed and the incidence of IE was calculated 2.97/100.000 person-years.
The mitral valve was infected in 35 patients (40%), aortic in 27 (31%) and
tricuspid in 9 (10%). In 19 cases a prosthetic valve was infected (22%),
one early (<60 days from procedure) and 18 late. Sixteen patients were
intravenous drug users. The most common causative organisms were
streptococcus (33%), staphylococcus (25%) and enterococcus (16%).
Surgical intervention was performed in 16 cases (18%). One and five year
survival was 77% and 57% respectively.
Conclusion: The incidence of IE in lceland is still low compared to other
countries. The clinical profile of the disease has changed since 1976-
85, patients with prosthetic heart valves and intravenous drug users
were more prominent than before. The microbiological spectrum has
not changed much, streptococcus is still the most common pathogen,
contrary to what is seen in other industrial countries where S. aureus
is more frequent. Death rate is lower than before and one year survival
good compared to other reports.
Key words: Endocarditis, heart valve, prosthetic valve, iv. drug use, vaive replacement surgery, incidence, survival.
Correspondence: Elin Björk Tryggvadóttir, ebtVShi.is
'Faculty of Medicine, 2University of lceland, Reykjavik, lceland, "Akureyri Hospital, Akureyri, lceland.
30 LÆKNAblaöið 2012/98